154 results on '"Grima D"'
Search Results
2. Obesity in Italian nurses: the role of physical activity in the workplace.
3. The Urbino Charter: a Declaration for the well-being of working people.
4. EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
5. Certification and prescription in the diabetology field: occupational and medico-legal aspects.
6. What to remove from the work environment: the sick worker or the cause of his sickness? Workplace bullying, a form of violence that causes sickness.
7. POSA148 Cost Effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
8. Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone
9. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis
10. PCV9 Health IMPACT of Tafamidis in Transthyretin Amyloid Cardiomyopathy Patients: An Analysis from the Attr-ACT and the OPEN-Label Extension Studies
11. Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions
12. PCN282 VALIDATION AND CALIBRATION OF A DISCRETE EVENT SIMULATION TREATMENT SEQUENCING MODEL TO ESTIMATE LONG-TERM SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA
13. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States
14. PDB6 LONG-TERM ASSOCIATION OF OBSERVED VERSUS PREDICTED MICRO- AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS: EXTERNAL VALIDATION OF THE CORNERSTONE DIABETES SIMULATION MODEL (CDSM)
15. PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODEL
16. Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
17. PF735 ECONOMIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (CML-CP) IN GERMANY
18. PCV26 A COMPARISON OF THE COSTS OF ATRIAL FIBRILLATION ABLATION USING RADIOFREQUENCY CONTACT FORCE AND CRYOBALLOON TECHNOLOGIES IN THE UNITED STATES: AN ANALYSIS OF PROPENSITY SCORE MATCHED POPULATIONS
19. CP2 ESTIMATING THE SURVIVAL AND COST IMPACT OF INTRODUCING FIRST-LINE ALECTINIB AND OSIMERTINIB FOR PATIENTS WITH ADVANCED NSCLC: AN ITEN MODEL ASSESSMENT
20. MA18.02 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation
21. PCN86 - VALIDATION OF THE IMPACT OF TREATMENT EVOLUTION IN NON-SMALL CELL LUNG CANCER (NSCLC) MODEL (ITEN): A DISCRETE EVENT PATIENT SIMULATION
22. P2.15-09 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017
23. Economic Guidance Panel Changes to Minimize Post-Progression Treatment Effects by the Pan-Canadian Oncology Drug Review in Economic Evaluations Assessing Cancer Drugs
24. Cancer Drug Recommendations Without Statistically Significant Overall Survival By The Pan-Canadian Oncology Drug Review
25. Cost-Effectiveness of Nilotinib Versus Dasatinib for The Second-Line Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Resistant or Intolerant To Imatinib, in Frame of Russian Healthcare System
26. 1582P - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
27. Insights into the Pan-Canadian Pharmaceutical Alliance’s Decision not to Collectively Negotiate Pricing for Drug Products
28. Use of a Decision Analytic Model to Assess the Clinical and Economic Impact of an Educational Program for Antimicrobial Use in a Dialysis Clinic
29. Pan-Canadian Oncology Drug Review Recommendations for Cancer Products without Statistically Significant Overall Survival Data
30. PCN226 - Positive Cancer Drug Recommendations By The Pan-Canadian Oncology Drug Review Are Not Without Conditions Placed On Cost-Effectiveness
31. PCN224 - Cancer Drug Recommendations Without Statistically Significant Overall Survival By The Pan-Canadian Oncology Drug Review
32. CN1 - Economic Guidance Panel Changes to Minimize Post-Progression Treatment Effects by the Pan-Canadian Oncology Drug Review in Economic Evaluations Assessing Cancer Drugs
33. The Assessment Of Value For Medical Devices: A Case Study On Injection Technique Education In Insulin Delivery
34. PCN164 - Cost-Effectiveness of Nilotinib Versus Dasatinib for The Second-Line Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Resistant or Intolerant To Imatinib, in Frame of Russian Healthcare System
35. PCN209 - Insights into the Pan-Canadian Pharmaceutical Alliance’s Decision not to Collectively Negotiate Pricing for Drug Products
36. PCN191 - Pan-Canadian Oncology Drug Review Recommendations for Cancer Products without Statistically Significant Overall Survival Data
37. PIN65 - Use of a Decision Analytic Model to Assess the Clinical and Economic Impact of an Educational Program for Antimicrobial Use in a Dialysis Clinic
38. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis
39. PUK14 CHALLENGES IN ASSESSING COST-EFFECTIVENESS OF THERAPIES FOR DIALYSIS PATIENTS: A CASE STUDY OF SEVELAMER FOR THE TREATMENT OF HYPERPHOSPHATEMIA
40. Cost-Effectiveness of Oxaliplatin in the Adjuvant Treatment of Colon Cancer in Canada
41. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis
42. POS6 IMPACT OF BISPHOSPHONATES ON OSTEOPOROTIC FRACTURES, PATIENT QUALITY OF LIFE AND TREATMENT COSTS:THE CASE OF GERMANY
43. PDB29 HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE-1 AND TYPE-2 DIABETES
44. POS2 CLINICAL AND ECONOMIC IMPACT OF RISEDRONATE TREATMENT FOR POST-MENOPAUSAL OSTEOPOROSIS IN FRANCE
45. PCN3 POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18
46. Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
47. PMD28 CHALLENGES FOR MODEL-BASED ECONOMIC EVALUATIONS OF GLAUCOMA AND OCULAR HYPERTENSION TREATMENTS
48. PIN18 PROJECTED CLINICAL BENEFITS AND COSTEFFECTIVENESS OF AN HPV 16/18 VACCINE
49. PAR6 ACUTE GOUTY ARTHRITIS: THE COSTEFFECTIVENESS OF A NEW SELECTIVE COX-2 INHIBITOR (ETORICOXIB) IN THE UK
50. PIN37 A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER: POTENTIAL IMPACT OF AN HPV 16/18 VACCINE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.